Related Experiment Video
Updated: Aug 25, 2026
A Preclinical Murine Model of Hepatic Metastases
Published on: September 27, 2014
Expression of matrix metalloproteinases in feline vaccine site-associated sarcomas
Kara C Sorensen1, Barbara E Kitchell, David J Schaeffer
1Department of Veterinary Clinical Medicine, College of Veterinary Medicine, University of Illinois, Urbana, IL 61802, USA.
Objectives:
To screen for expression of 9 predominant members of the matrix metalloproteinase (MMP) family, including membrane-type matrix metalloproteinases (MT-MMPs) and tissue inhibitors of metalloproteinases (TIMPs), in primary tumor tissue biopsy specimens of vaccine site-associated sarcomas (VSS) in cats and compare expression profiles of VSS with expression profiles of non-VSS and carcinomas.
Sample Population:
31 primary tumor tissue biopsy specimens and 6 nontumor (normal) tissue biopsy specimens.
Procedures:
Tissue specimens were obtained from primary tumor biopsy specimens of cats. Primers for reverse transcriptase-polymerase chain reaction assay were designed on the basis of known sequences. Data were analyzed for patterns of expression of MMPs, MT-MMPs, and TIMPs. Differences in expression patterns were evaluated among cats of differing genders, ages, metastasis status, and overall survival durations, and between cats with VSS and cats with non-VSS tumor types.
Results:
A total of 31 primary tumor tissue biopsy specimens and 6 nontumor (normal) tissue biopsy specimens were screened for the presence of 6 MMPs and 3 TIMPs. Matrix metalloproteinase and TIMP expression was found in non-VSS, carcinomas, and VSS. No significant differences were found in patterns of expression among tumor types. Metastasis was found to be the only predictive factor for overall survival duration. A significant correlation was found between MMP2 and MT-MMP16 expression and overall duration of survival.
Conclusions And Clinical Relevance:
The identification of MMPs in feline VSS supports an underlying inflammatory pathogenesis for this tumor. Expression of MMP2 and MT-MMP16 were correlated with survival time in our study.
Insights
Matrix metalloproteinases (MMPs) and tissue inhibitors of metalloproteinases (TIMPs) are present in feline vaccine site-associated sarcomas (VSS). MMP2 and MT-MMP16 expression correlated with survival, suggesting an inflammatory role in VSS.
Area of Science:
- Veterinary Oncology
- Cancer Biology
- Molecular Pathology
Background:
- Vaccine site-associated sarcomas (VSS) are a type of feline cancer.
- Matrix metalloproteinases (MMPs) and tissue inhibitors of metalloproteinases (TIMPs) are key regulators of tissue remodeling and have been implicated in cancer progression.
Purpose of the Study:
- To screen for the expression of specific matrix metalloproteinases (MMPs) and tissue inhibitors of metalloproteinases (TIMPs) in feline vaccine site-associated sarcomas (VSS).
- To compare the expression profiles of VSS with non-VSS tumors and carcinomas in cats.
- To investigate the correlation between MMP and TIMP expression and clinical outcomes in cats with VSS.
Main Methods:
- Screening of 31 primary tumor biopsy specimens and 6 normal tissue biopsy specimens from cats.
- Utilizing reverse transcriptase-polymerase chain reaction (RT-PCR) assay to detect the expression of 6 MMPs and 3 TIMPs.
- Analyzing expression patterns in relation to tumor type, gender, age, metastasis, and survival duration.
Main Results:
- MMP and TIMP expression was detected in VSS, non-VSS tumors, and carcinomas.
- No significant differences in expression patterns were observed among the different tumor types.
- Metastasis was identified as the sole predictive factor for overall survival.
- A significant correlation was found between the expression of MMP2 and MT-MMP16 and the overall duration of survival.
Conclusions:
- The presence of MMPs in feline VSS supports an underlying inflammatory pathogenesis.
- Expression levels of MMP2 and MT-MMP16 are correlated with survival time in cats with VSS.
- These findings may contribute to understanding the biology of VSS and developing targeted therapies.
